LeonaBio Inc Financials
This page shows LeonaBio Inc (LONA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of LeonaBio Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
LeonaBio Inc has a moderate D/E ratio of 2.32. This balance of debt and equity financing earns a leverage score of 55/100.
LeonaBio Inc's current ratio of 1.88 indicates adequate short-term liquidity, earning a score of 34/100. The company can meet its near-term obligations, though with limited headroom.
LeonaBio Inc generates a -380.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -216.2% the prior year.
LeonaBio Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, LeonaBio Inc generates $0.43 in operating cash flow (-$45.7M OCF vs -$105.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
LeonaBio Inc's EBITDA was -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.4% from the prior year.
LeonaBio Inc reported -$105.6M in net income in fiscal year 2025. This represents a decrease of 8.9% from the prior year.
LeonaBio Inc earned $-24.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1.9% from the prior year.
Cash & Balance Sheet
LeonaBio Inc held $69.3M in cash against $0 in long-term debt as of fiscal year 2025.
LeonaBio Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 139.1% from the prior year.
Margins & Returns
LeonaBio Inc's ROE was -380.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 163.8 percentage points from the prior year.
Capital Allocation
LeonaBio Inc invested $17.5M in research and development in fiscal year 2025. This represents a decrease of 75.2% from the prior year.
LONA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $2.8M-22.8% | $3.7M-14.9% | $4.3M | N/A | $17.9M-19.1% | $22.2M+4.3% | $21.2M |
| SG&A Expenses | N/A | $4.0M+11.5% | $3.6M-30.6% | $5.2M | N/A | $7.6M+28.9% | $5.9M-8.9% | $6.5M |
| Operating Income | N/A | -$6.9M+5.7% | -$7.3M+23.5% | -$9.5M | N/A | -$29.6M-5.7% | -$28.0M-1.2% | -$27.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$6.6M+5.1% | -$7.0M+23.8% | -$9.1M | N/A | -$28.7M-7.0% | -$26.9M-2.0% | -$26.3M |
| EPS (Diluted) | N/A | $-1.68 | $-0.18+21.7% | $-0.23 | N/A | $-7.46-965.7% | $-0.70-1.4% | $-0.69 |
LONA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $92.2M+206.8% | $30.0M-15.5% | $35.5M-18.3% | $43.5M-26.0% | $58.8M-31.8% | $86.2M-22.5% | $111.3M-16.6% | $133.5M |
| Current Assets | $89.5M+231.0% | $27.0M-16.1% | $32.2M-19.2% | $39.9M-27.3% | $54.8M-33.1% | $82.0M-23.2% | $106.7M-17.0% | $128.6M |
| Cash & Equivalents | $69.3M+231.9% | $20.9M+5.0% | $19.9M-24.7% | $26.4M-45.5% | $48.4M-29.7% | $68.9M-6.7% | $73.8M-5.1% | $77.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $64.4M+1882.2% | $3.2M-8.8% | $3.6M-42.4% | $6.2M-55.6% | $13.9M-51.4% | $28.7M+2.7% | $27.9M+4.5% | $26.7M |
| Current Liabilities | $47.5M+1604.4% | $2.8M-6.5% | $3.0M-45.7% | $5.5M-58.2% | $13.1M-52.7% | $27.8M+3.2% | $26.9M+5.1% | $25.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $27.8M+3.7% | $26.8M-16.3% | $32.0M-14.3% | $37.3M-16.8% | $44.8M-22.1% | $57.6M-30.9% | $83.3M-21.9% | $106.7M |
| Retained Earnings | -$511.8M-19.3% | -$428.9M-1.6% | -$422.3M-1.7% | -$415.3M-2.3% | -$406.1M-3.8% | -$391.1M-7.9% | -$362.4M-8.0% | -$335.5M |
LONA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.4M-315.5% | -$4.7M+33.3% | -$7.0M+52.3% | -$14.7M+43.6% | -$26.0M-13.0% | -$23.0M-3.1% | -$22.3M+13.5% | -$25.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $28K+460.0% | $5K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$26.0M-13.0% | -$23.0M-3.0% | -$22.4M+13.4% | -$25.8M |
| Investing Cash Flow | -$14.6M-358.9% | $5.7M+1182.1% | $441K+106.0% | -$7.4M-161.4% | -$2.8M-115.6% | $18.0M-32.1% | $26.6M+103.7% | $13.0M |
| Financing Cash Flow | $82.4M | $0 | N/A | N/A | $34K+183.3% | $12K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LONA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -24.7%-2.9pp | -21.8%+2.7pp | -24.5% | N/A | -49.9%-17.7pp | -32.2%-7.6pp | -24.7% |
| Return on Assets | N/A | -22.0%-2.4pp | -19.6%+1.4pp | -21.0% | N/A | -33.3%-9.2pp | -24.1%-4.4pp | -19.7% |
| Current Ratio | 1.88-7.8 | 9.70-1.1 | 10.81+3.6 | 7.26+3.1 | 4.18+1.2 | 2.95-1.0 | 3.97-1.1 | 5.03 |
| Debt-to-Equity | 2.32+2.2 | 0.120.0 | 0.11-0.1 | 0.17-0.1 | 0.31-0.2 | 0.50+0.2 | 0.34+0.1 | 0.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is LeonaBio Inc profitable?
No, LeonaBio Inc (LONA) reported a net income of -$105.6M in fiscal year 2025.
What is LeonaBio Inc's EBITDA?
LeonaBio Inc (LONA) had EBITDA of -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is LeonaBio Inc's return on equity (ROE)?
LeonaBio Inc (LONA) has a return on equity of -380.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LeonaBio Inc's operating cash flow?
LeonaBio Inc (LONA) generated -$45.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are LeonaBio Inc's total assets?
LeonaBio Inc (LONA) had $92.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does LeonaBio Inc spend on research and development?
LeonaBio Inc (LONA) invested $17.5M in research and development during fiscal year 2025.
What is LeonaBio Inc's current ratio?
LeonaBio Inc (LONA) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.
What is LeonaBio Inc's debt-to-equity ratio?
LeonaBio Inc (LONA) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LeonaBio Inc's return on assets (ROA)?
LeonaBio Inc (LONA) had a return on assets of -114.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LeonaBio Inc's cash runway?
Based on fiscal year 2025 data, LeonaBio Inc (LONA) had $69.3M in cash against an annual operating cash burn of $45.7M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is LeonaBio Inc's Piotroski F-Score?
LeonaBio Inc (LONA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LeonaBio Inc's earnings high quality?
LeonaBio Inc (LONA) has an earnings quality ratio of 0.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is LeonaBio Inc?
LeonaBio Inc (LONA) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.